Maxim analyst Jason McCarthy downgraded Iterum Therapeutics (ITRM) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM:
- Iterum Therapeutics Appeals Nasdaq Delisting, Explores Strategic Alternatives
- Morning News Wrap-Up 3/3/26: Tuesday’s Biggest Stock Market Stories!
- Why Is Iterum Therapeutics Stock (ITRM) Down Today?
- Iterum Therapeutics Faces Nasdaq Delisting, Weighs Strategic Options
- Iterum Therapeutics Shareholders Reject Key Capital Proposals